Looking forward to the weekend? We are, too. But first, let’s look back at a few news stories we covered that are still making waves.

— Our April issue is now available, and there’s a special focus on counterfeit drugs. One of the stories describes Uganda’s controversial Anticounterfeit Goods Bill, which some say goes too far in its definition of ‘counterfeit’ and could end up limiting access to generics. A bill that could supersede the Ugandan one is in the works among the five-nation East African Community, but that bill is also facing criticism now because it could limit access to antiretrovirals. In other counterfeiting news, US federal prosecutors have charged two Chinese men for importing and selling counterfeit drugs, including a fake version of the diet drug Alli.

— We also had a special news focus last month on electronic health records (EHRs). Health Affairs tackled the topic this month with its own section, featuring a study on how the US Department of Veteran Affairs (VA) utilized an electronic system. While the authors note many caveats, they say that EHRs might have saved the VA as much as $3.1 billion over the course of a decade. Also in the news recently, Pfizer said it is piloting projects that use electronic medical records and mobile technology to better track adverse events among patients; sounds like our coverage of secondary data use and even mobile medicine.

— You might have already forgotten about February’s Winter Olympic Games, but hopefully you haven’t forgotten our coverage of the athlete biological passport, a new initiative to prevent doping. Well, looking forward to London 2012, the World Anti-Doping Agency revealed that it has almost finished developing its biomarkers test for human growth hormone; the compound has been in the news recently after a rugby player tested positive and was suspended for two years. Looking even further ahead to Rio de Janeiro 2016, Brazil announced the development of a $7 million sports center that would also conduct studies of biochemistry and physiology among athletes.

— Lastly, our February issue featured the potential of algae, rather than yeast, for drug production. Now, yeast are getting another knock against them. Researchers found that secretion rates vary widely among individual yeast cells, spurring the need for a new look at how to increase productivity — or maybe another look at algae.

Illustration by Alyssa Grenning